Business context and reporting period
VistaGen Therapeutics, Inc. filed this Form 10-K for the fiscal year ended March 31, 2015—not a standalone calendar-year 2014 fourth quarter. The filing includes unaudited quarterly results; fiscal Q4 ended March 31, 2015. VistaGen is a clinical-stage biopharmaceutical company with no approved products or product-sale revenue. Its lead candidate, oral AV-101, was being prepared for an NIH/NIMH-sponsored Phase 2 study in treatment-resistant major depressive disorder (MDD). The company also pursued stem-cell-based drug-rescue research.
Financial performance and position
| Metric | FY ended Mar. 31, 2015 | FY ended Mar. 31, 2014 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $2.43 million | $2.48 million |
| General and administrative expense | $4.34 million | $2.55 million |
| Total operating expenses / operating loss | $6.78 million | $5.03 million |
| Net loss | $13.89 million | $2.97 million |
| Net loss per basic share | $10.53 | $2.70 |
| Net cash used in operations | $2.77 million | $2.13 million |
| Cash at year-end | $70,000 | $0 |
General and administrative expense rose about 70%, while R&D expense declined about 2%; total operating expenses increased about 35%. The net loss widened substantially, reflecting higher interest expense, including $3.37 million of note-discount amortization, a $2.39 million noncash loss on debt extinguishment, and a small warrant-liability loss. Stock-based compensation was $2.46 million, also primarily noncash. With no revenue, gross margin and operating margin are not meaningful.
At March 31, 2015, total assets were $269,700, including $70,000 cash; current assets were $105,700 versus current liabilities of $17.39 million. Total liabilities were $20.81 million, and stockholders’ deficit was $20.54 million. The company reported $3.01 million in warrant liability. Operating cash outflow increased from the prior year; financing provided $2.84 million in FY2015. The filing says approximately $7 million of financing was needed over the following 12 months to execute its plan.
Material changes and developments
- Net loss increased from $2.97 million to $13.89 million, while revenue remained zero.
- G&A increased by $1.80 million, including higher stock-based compensation and professional fees; R&D spending was broadly flat.
- In February 2015, VistaGen entered a CRADA with NIMH for a Phase 2 AV-101 MDD study to be conducted and funded by NIH. Management expected the study to start in 2015; the filing also anticipated completion in 2016.
- After year-end, financing and debt conversions materially changed the capital structure. By June 25, 2015, the company reported eliminating approximately $14.9 million of debt through conversion principally into Series B preferred stock, alongside $557,500 of Series B unit proceeds. These transactions reduced near-term debt obligations but created substantial potential dilution and did not remove the need for further capital.
Outlook, commentary, risks and unusual items
Management expected continued operating losses and negative operating cash flows while advancing AV-101 and drug-rescue programs. The planned NIH-sponsored Phase 2 study reduced direct study-funding needs for that trial, but did not fund the company’s overall operations. No quantified revenue or earnings guidance was provided.
- The independent auditor expressed substantial doubt about VistaGen’s ability to continue as a going concern. The statements were prepared on a going-concern basis and included no adjustments for the uncertainty. At March 31, cash was insufficient to fund the next 12 months; future financing was not assured.
- AV-101 remained dependent on successful clinical testing, regulatory approval, and later commercialization. The filing cautions that Phase 1 safety findings and preclinical results do not establish efficacy or predict later-stage outcomes.
- Other key risks include reliance on third-party manufacturers, CROs and collaborators; limited personnel and resources; competition; uncertain patent protection (the filing says no AV-101 patents had issued); and potential dilution or restrictive financing terms.
- Executives accepted substantially reduced cash pay, with unpaid compensation accrued. The company also issued significant warrants and shares for services, contributing to noncash expense and dilution.
- The filing contains an apparent inconsistency: MD&A and the audited statements report FY2015 R&D expense of $2.43 million, while a financial-statement note states approximately $4.3 million for FY2015. The filing text does not reconcile the figures clearly.
Most important facts for investors to verify
- Current cash, monthly cash burn, remaining financing runway, and whether additional funding was secured on acceptable terms after the filing date.
- Completion, timing, design, enrollment, results and safety findings of the NIH/NIMH Phase 2 AV-101 study.
- The final terms, conversion rights, dividends, warrants and fully diluted share impact of the Series B financing and debt conversions.
- Reconciliation of the reported FY2015 R&D expense figures and confirmation of the company’s subsequent liquidity and going-concern status.
- Progress in obtaining enforceable AV-101 patent protection and validating the commercial and predictive value of CardioSafe 3D and LiverSafe 3D.